Literature DB >> 3813517

Epidemiology of intestinal colonization by members of the family Enterobacteriaceae resistant to cefotaxime in a hematology-oncology unit.

M H Prevot, A Andremont, H Sancho-Garnier, C Tancrede.   

Abstract

Intestinal colonization by members of the family Enterobacteriaceae resistant to cefotaxime was surveyed for 3 years in a hematology-oncology unit. Of 416 patients, 66 (15.9%) were colonized, each with a different strain. The incidence of intestinal carriage was not correlated with cefotaxime consumption in the ward but was strongly associated with individual exposure to cefotaxime.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3813517      PMCID： PMC180626          DOI： 10.1128/AAC.30.6.945

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit.

Authors:  A Andremont; H Sancho-Garnier; C Tancrede
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

2.  Development of resistance to beta-lactam antibiotics with special reference to third-generation cephalosporins.

Authors:  E Collatz; L Gutmann; R Williamson; J F Acar
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

3.  Antibacterial activity of cefotaxime.

Authors:  S Mitsuhashi; M Inoue; S Masuyoshi
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

Review 4.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

5.  Incidence of trimethoprim-sulfamethoxazole-resistant enterobacteriaceae among transplant recipients.

Authors:  C L Wells; R P Podzorski; P K Peterson; N K Ramsay; R L Simmons; F S Rhame
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

6.  [Combined cefotaxime-amikacin treatment of infectious episodes in acute leukaemia patients with therapeutically-induced bone marrow aplasia (author's transl)].

Authors:  H Guy; P Chavanet; H Portier; A Kazmierczak; P Cortet
Journal:  Nouv Presse Med       Date:  1981-02-26

7.  Epidemiology of enterobacteria resistant to cefotaxime in hospital.

Authors:  C H Tancrede; A O Andremont; F C Leonard
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

8.  Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital.

Authors:  V Jarlier; R Bismuth; M H Nicolas; J Nguyen; C Truffot; J Grosset
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  [Enterobacter cloacae and E. aerogenes septicemia: emergence of resistant variants (derepressed cephalosporinase) during treatment with third-generation cephalosporins].

Authors:  C Nauciel; A Philippon; E Ronco; J Pilliot; M Guenounou; G Paul; D Brunel; H D Outin
Journal:  Presse Med       Date:  1985-03-23       Impact factor: 1.228

10.  Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies.

Authors:  C H Tancrède; A O Andremont
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226
View more
  7 in total

Review 1.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 2.  Use of plasmid profiles in epidemiologic surveillance of disease outbreaks and in tracing the transmission of antibiotic resistance.

Authors:  L W Mayer
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Antibiotic treatment and intestinal colonization by Pseudomonas aeruginosa in cancer patients.

Authors:  A Andremont; B Marang; C Tancrède; D Baume; C Hill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Emergence of cross-resistance to beta-lactam antibiotics in fecal Escherichia coli and Klebsiella strains from neonates treated with ampicillin or cefuroxime.

Authors:  K Tullus; B Berglund; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  Cefotaxime combined with selective decontamination in long term intensive care unit patients. Virtual absence of emergence of resistance.

Authors:  H K van Saene; C P Stoutenbeek; D F Zandstra
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Impact of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in children in a low resistance prevalence setting.

Authors:  Per Kristian Knudsen; Petter Brandtzaeg; E Arne Høiby; Jon Bohlin; Ørjan Samuelsen; Martin Steinbakk; Tore G Abrahamsen; Fredrik Müller; Karianne Wiger Gammelsrud
Journal:  PLoS One       Date:  2017-11-07       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.